Vivos Therapeutics, Inc. (VVOS)

From the record

Vivos Therapeutics, Inc.'s filings since 2017 show 20 warning events of 4 kinds: a notice about its exchange listing (8-K item 3.01, 9 times, the latest 2026-06-08); a warning not to rely on past financial statements (8-K item 4.02, the latest 2022-11-22); an auditor change (8-K item 4.01, 3 times, the latest 2026-10-01); a late-report notice (Form NT 10-K or NT 10-Q, 7 times, the latest 2026-05-15) (its current reports).

From the record

Vivos Therapeutics, Inc.'s 7 filed years say what it did: revenue went from $11 million in fiscal 2019 to $17 million in fiscal 2025, up 7.4% a year; it rose in 4 of 6 years; the deepest fall was 18% from fiscal 2021 to fiscal 2023; net income was positive in 0 of 7 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Vivos Therapeutics, Inc.'s shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 42 cents per dollar of everything the company owns. Leverage: it owed about 106 cents per dollar of assets, and net share issuance: its share count grew 104.7% over the year (the filed statements).

From the record

Vivos Therapeutics, Inc.'s standing among 109 graded names in its industry family: revenue of $17 million in fiscal 2025 ranks in the bottom 26% by size; a net margin of -121.4% ranks in the bottom 24%; revenue growth of 2.9% a year over the last 3 filed years ranks in the bottom 28% (its annual reports).

From the record

Vivos Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Huntsman, Ronald Kirk (Chief Executive Officer, as filed), filing under that title since 2020-12-10, 5.9 years (top 42% of its family); the 7 officers and directors filing in the last fifteen months have been on the record a median of 5.9 years (top 43%); 4 officer or director changes were reported on Form 8-K since 2023-11-13, against the 7 people in charge now (bottom 46%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Vivos Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $2 million against debt of $753 thousand leaves 5.1% of its assets as net cash, bottom 41% of its family; cash from operations less capital spending is -100.9% of revenue (bottom 22%); a gross margin of 60.4% (bottom 49%); research spending of 0.6% of revenue (bottom 3%) (its annual report).

From the record

Vivos Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 2.9% a year over the last three filed years against 7.4% over all 7, slowing (bottom 37% of its family); the newest year grew 16.1% (top 41%); research spending grew -20.6% a year (bottom 5%); capital spending grew 36.3% a year (top 13%) (its annual reports). Vivos Therapeutics, Inc. reported 8 product lines in fiscal 2025: Sleep Testing Services at $6 million (35%), Appliances at $3 million (19%), Tooth Positioners at $3 million (18%), and 5 more; 2 of 7 grew against the year before (its annual report).

From the record

Vivos Therapeutics, Inc.'s newest year against its own record: revenue of $17 million in fiscal 2025 came in 19.8% above the $15 million its prior three years' pace pointed to (top 10% of its family); net income of $21 million against a prior three-year average of $16 million (bottom 21%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 11%) (its annual reports).